Lysophosphatidic acid signaling in cancer cells: what makes LPA so special?

P Balijepalli, CC Sitton, KE Meier - Cells, 2021 - mdpi.com
Lysophosphatidic acid (LPA) refers to a family of simple phospholipids that act as ligands for
G protein-coupled receptors. While LPA exerts effects throughout the body in normal …

Metastasis prevention: targeting causes and roots

AA Schegoleva, AA Khozyainova… - Clinical & Experimental …, 2022 - Springer
The spread of tumor cells from the primary focus, metastasis, is the main cause of cancer
mortality. Therefore, anticancer therapy should be focused on the prevention of metastatic …

[HTML][HTML] The lysophosphatidic acid-regulated signal transduction network in ovarian cancer cells and its role in actomyosin dynamics, cell migration and entosis

K Ojasalu, S Lieber, AM Sokol, A Nist, T Stiewe… - Theranostics, 2023 - ncbi.nlm.nih.gov
Lysophosphatidic acid (LPA) species accumulate in the ascites of ovarian high-grade
serous cancer (HGSC) and are associated with short relapse-free survival. LPA is known to …

Influence of the autotaxin-lysophosphatidic acid axis on cellular function and cytokine expression in different breast cancer cell lines

T Hauck, S Kadam, K Heinz, M Garcia Peraza… - Scientific Reports, 2022 - nature.com
Previous studies provide high evidence that autotaxin (ATX)-lysophosphatidic acid (LPA)
signaling through LPA receptors (LPAR) plays an important role in breast cancer initiation …

Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl) carbamoyl) piperidin-1-yl)-4 …

C Lescop, C Brotschi, JT Williams… - Journal of Medicinal …, 2024 - ACS Publications
Lysophosphatidic acid receptor 1 (LPAR1) antagonists show promise as potentially novel
antifibrotic treatments. In a human LPAR1 β-arrestin recruitment-based high-throughput …

Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases

C Lescop, M Birker, C Brotschi, C Bürki… - Journal of Medicinal …, 2024 - ACS Publications
Piperidine 3 is a potent and selective lysophosphatidic acid receptor subtype 1 receptor
(LPAR1) antagonist that has shown efficacy in a skin vascular leakage target engagement …

[HTML][HTML] Roles of autotaxin/autotaxin-lysophosphatidic acid axis in the initiation and progression of liver cancer

S She, Q Zhang, J Shi, F Yang, K Dai - Frontiers in Oncology, 2022 - frontiersin.org
Autotaxin (ATX) is a secreted glycoprotein and catalyzes the hydrolysis of
lysophosphatidylcholine to lysophosphatidic acid (LPA), a growth factor-like signaling …

Review of Eukaryote Cellular Membrane Lipid Composition, with Special Attention to the Fatty Acids

O Ali, A Szabó - International Journal of Molecular Sciences, 2023 - mdpi.com
Biological membranes, primarily composed of lipids, envelop each living cell. The intricate
composition and organization of membrane lipids, including the variety of fatty acids they …

The crosstalk of the human microbiome in breast and colon cancer: a metabolomics analysis

AG Mukherjee, UR Wanjari, P Bradu, R Murali… - Critical Reviews in …, 2022 - Elsevier
The human microbiome's role in colon and breast cancer is described in this review.
Understanding how the human microbiome and metabolomics interact with breast and colon …

Integration of an LPAR1 antagonist into liposomes enhances their internalization and tumor accumulation in an animal model of human metastatic breast cancer

RG Abdelmessih, J Xu, FR Hung… - Molecular …, 2023 - ACS Publications
Lysophosphatidic acid receptor 1 (LPAR1) is elevated in breast cancer. The deregulation of
LPAR1, including the function and level of expression, is linked to cancer initiation …